DYSEMBRYOGENETIC STIGMATA AND PHYSICAL DEVELOPMENT IN CHILDREN BORN TO EPILEPTIC MOTHERS
Abstract
To investigate physical development and dysembryogenetic stigmata in children born to epileptic mothers. Materials: 50 patients (main group) are children born to epileptic mothers, and 50 children (control group) who are born to somatically healthy mothers. Study method: clinico-neurological method. Results: For the moment of investigation, no reliable, statistically significant differences in body mass, height, head or chest circumference have been found between the group of children born to epileptic mothers and group of children born to somatically healthy mothers (р > 0.05). In 20 (40%) of examined children the dysembryogenetic stigmata were found. Statistically significant changes in children born to epileptic mothers, and having dysembryogenetic stigmata, were found as compared to children born to somatically healthy mothers. Conclusions. 1) The rate of dysembryogenetic stigmata found in children born to epileptic mothers, who took anti-epileptic drugs (AED) during pregnancy, exceeds by approximately 10-fold the population indices. 2) Physical development of children born to epileptic mothers did not differ from that of children born to somatically healthy mothers. 3) The choice of AED for treatment during pregnancy should take into account the AED relative teratogenic potential (development of congenital abnormalities and effect on further cognitive development), as well as AED efficiency against seizures during pregnancy, depending on the form of epilepsy.
About the Authors
A. B. Kozhokaru
Moscow State Medical and Dental University, and Medical Center «Neuromed-Clinic», Moscow
Russian Federation
Department of Neurology
Russian Federation
Department of Neurology
V. A. Karlov
Moscow State Medical and Dental University, and Medical Center «Neuromed-Clinic», Moscow
Russian Federation
Department of Neurology
Russian Federation
Department of Neurology
I. A. Zhidkova
Moscow State Medical and Dental University, and Medical Center «Neuromed-Clinic», Moscow
Russian Federation
Department of Neurology
Russian Federation
Department of Neurology
A. V. Serkina
Moscow State Medical and Dental University, and Medical Center «Neuromed-Clinic», Moscow
Russian Federation
Department of Neurology
Russian Federation
Department of Neurology
References
1. Карлов В.А., Власов П.Н., Краснопольский В.И., Петрухин В.А. Особенности терапевтической тактики при эпилепсии во время беременности. Российский вестник акушера-гинеколога 2002; 3:63-68.
2. Dansky L.V., Finnell R.H. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiological and experimental findings spanning three decades; 2: human studies. Reprod Toxicol 1991; 5:301-335.
3. Paskind HA., Brown M.. Constitutional differences between deteriorated and nondeteriorated patients with epilepsy. Arch Neurol Psychiatry 1936; 36:1037– 1044.
4. Middaugh L.D., Santos C.A. 3rd, Zemp J.W. Effects of Phenobarbital given to pregnant mice on behavior of mature offspring. Dev Psychobiol 1975; 8:305-13.
5. Yanai J., Rosselli-Austin L., Tabakoff B. Neuronal deficits in mice following prenatal exposure to phenobarbital. Exp Neurol 1979; 64:237-44.
6. Vorhees C.V. Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats. Psychopharmacology 1987; 92:173-9. 7. Vorhees C.V. Minck D.R. Long-term effects of prenatal phenytoin exposure on offspring behavior in rats. Teurotoxicol Teratol 1989; 11:295-305.
7. Yerby M.S. Pregnancy and epilepsy. Epilepsia 1991; 32:S51-S59.
8. Лукок М.Д., Уэйтс З.А. Роль фолата в болезнях роста, сосудистых заболеваниях и других клинических состояниях: Важность содержания фолата и генотипа. В книге под ред. Массаро Е.Дж. «Фолат и развитие человека». Totowa, NJ, Humana Press, 2001; 263-98.
9. Milunsky A, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989;262:2847-52.
10. Steegers-Theunissen R., Wathen N., Eskes human pregnancy. Br. J. Obstet. Gynaecol. 1997; 104:20–24.
11. Boddie A., Dedlow R., Nackashi J., Opalko J., Kauwell G., Gregory J., Bailey L. Folate absorption in women with a history of neural tube defect affected pregnancy. Am J Clin Nutr 2000; 72: 154-158.
12. Murphy M., Whiteman D., Stone D., Botting B., Schorah C., Wild J. Dietary folate and the prevalence of neural tube defects in the British Isles: the past two decades. BJOG 2000; 107:885-9.
13. Ogawa Y., Kaneko S., Otani K., Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8:75-8.
14. Dansky L. V., Rosenblatt D.S. and Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992; 42:32-42.
15. Kishi T., Fujita N., Eguchi T., Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997; 145: 109-112.
16. Apeland T., Mansoor M.A., Standjord R.E. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 2001; 47:27-35.
17. Wegner C., Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 1992; 42:17-24.
18. Finnell RH, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology. 1992; 42:25-31.
19. Buehler B.A., Delimont D., Waes M.V., Finnell R. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl. J. Med. 1990; 322: 1567-1572.
20. Wells P.G., Kupfer A., Lawson J.A., Harbison R.D. Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: evaluation of mephenytoin and its metabolite. J Pharmacol Exp Ther 1982; 221:228-234.
21. Lindhout D. Pharmacokinetics and drugs interactions: role in antiepileptic drug induced teratogenesis. Neurology 1992; 42:32-42.
22. Steinhausen H.C., Losche G., Koch S., Helge H. The psychological development of children of epileptic parents: study design and comparative findings. Acta paediatr 1994; 3:955-60.
23. Janz D., Fuchs U. Antiepileptische Medikamente Waehrend der schwangerschaft schaedlich? Dtsch Med Wochenschr. 1964;89:241–248.
24. Meadow SR. Anticonvulsant drugs and congenital abnormalities. Lancet 1968; 2:1296.
25. Robert E., Guibaund P. Maternal valproic acid and congenital neural tub defects. Lancet 1982; 2:937.
26. Kanenko S., Battino D., Andermann E. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33:145-58.
27. Levitt A., Yerby M., Robinson N., Sells C., Erikson D. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology. 1992; 42: 141-143.
28. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Perucca E., Sabers A., Vajda F. EURAP: An International Registry of antiepileptic drugs and pregnancy. Epilepsia 2004; 45(11):1463-1464.
29. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Perucca E., Sabers A. EURAP: An International Registry of antiepileptic drugs and pregnancy. Interim Report. November 2008; 1-15.
30. Tomson T. Management of epilepsy in pregnancy. Epilepsy in modern medicine. Eds. Gusev E.I., Guekht A.B. Proceedings of the conference 2009; 407-421.
31. Доброхотова Ю.Э., Гехт А.Б., Локшина О.Б., Шин С.М.Б Ухтунова Ю.М. Особенности течения беременности у женщин, страдающих эпилепсией (обзор литературы). Проблемы репродукции 2005; 4:51-56.
32. Crawford P. Best Practice Guidelines for the Management of Women with Epilepsy. Epilepsia 2005; 46 (9):117-24/
33. Yerby M S. Teratogenicity and antiepileptic drugs: potential mechanisms. Int Rev Neurobiol. 2008;83:181-204.
34. Morrell MJ, Sarto GE, Osborne Shafer P, Borda EA, Herzog A, Callanan M. Health issues for women with epilepsy: a descriptive survey to assess knowledge and awareness among healthcare providers. J Womens Health Gend Based Med 2000;9:959-965.
35. Kaneko S., Otani K., Fukushima Y., Ogawa Y., Nomura Y., Ono T. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988; 29: 459-467.
Review
For citations:
Kozhokaru A.B., Karlov V.A., Zhidkova I.A., Serkina A.V. DYSEMBRYOGENETIC STIGMATA AND PHYSICAL DEVELOPMENT IN CHILDREN BORN TO EPILEPTIC MOTHERS. Epilepsy and paroxysmal conditions. 2010;2(2):25-31. (In Russ.)
Views:
2103
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
